Eli Lilly and Co
(XPAR:LLY)
€
98
0 (0%)
Market Cap: 97.40 Bil
Enterprise Value: 122.86 Bil
PE Ratio: 87.15
PB Ratio: 50.94
GF Score: 87/100 Eli Lilly and Co at Barclays Global Healthcare Conference Transcript
Mar 15, 2022 / 02:15PM GMT
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Okay. Good morning, and welcome to the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. It's good to see all of you in person today.
I'm pleased to welcome Lilly to the stage. We are [overweight] Eli Lilly and see a differentiated and compelling commercial portfolio and a pipeline with really attractive opportunities across metabolic health, neuro, oncology and immunology. Representing the company is Patrik Jonsson, President of Lilly Immunology, Lilly USA and Chief Customer Officer. Patrik, thank you very much for joining us.
Patrik Jonsson
Eli Lilly and Company - Senior VP, Chief Customer Officer, President of Lilly USA & President of Lilly Immunology
Thank you very much, Carter.
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Great. So I think before we get into the Q&A, Patrik was just going to make some opening comments to kind of give
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot